Risk of prolonged sedation with the use of chlordiazepoxide in alcohol withdrawal treatment

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Risk of prolonged sedation with the use of chlordiazepoxide in alcohol withdrawal treatment. / Reiter, Nanna; Andersen, Charlotte U.; Thomsen, Karen L.; Wamberg, Christian A.; Petersen, Tonny S.; Dalhoff, Kim.

I: Adverse Drug Reaction Bulletin, Bind 340, Nr. 1, 01.06.2023, s. 1319-1322.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Reiter, N, Andersen, CU, Thomsen, KL, Wamberg, CA, Petersen, TS & Dalhoff, K 2023, 'Risk of prolonged sedation with the use of chlordiazepoxide in alcohol withdrawal treatment', Adverse Drug Reaction Bulletin, bind 340, nr. 1, s. 1319-1322. https://doi.org/10.1097/FAD.0000000000000068

APA

Reiter, N., Andersen, C. U., Thomsen, K. L., Wamberg, C. A., Petersen, T. S., & Dalhoff, K. (2023). Risk of prolonged sedation with the use of chlordiazepoxide in alcohol withdrawal treatment. Adverse Drug Reaction Bulletin, 340(1), 1319-1322. https://doi.org/10.1097/FAD.0000000000000068

Vancouver

Reiter N, Andersen CU, Thomsen KL, Wamberg CA, Petersen TS, Dalhoff K. Risk of prolonged sedation with the use of chlordiazepoxide in alcohol withdrawal treatment. Adverse Drug Reaction Bulletin. 2023 jun. 1;340(1):1319-1322. https://doi.org/10.1097/FAD.0000000000000068

Author

Reiter, Nanna ; Andersen, Charlotte U. ; Thomsen, Karen L. ; Wamberg, Christian A. ; Petersen, Tonny S. ; Dalhoff, Kim. / Risk of prolonged sedation with the use of chlordiazepoxide in alcohol withdrawal treatment. I: Adverse Drug Reaction Bulletin. 2023 ; Bind 340, Nr. 1. s. 1319-1322.

Bibtex

@article{910021b1110a4f348d51c35d15f814e0,

title = "Risk of prolonged sedation with the use of chlordiazepoxide in alcohol withdrawal treatment",

abstract = "SummaryThe use of chlordiazepoxide in the treatment of alcohol withdrawal symptoms poses a risk of prolonged sedation with the need of weeks lasting antidote treatment, and extended hospitalization due to active metabolites with very long half-lives.We present four case stories to elucidate this issue. One patient received 800 mg chlordiazepoxide and was treated with flumazenil for 42 days. Another patient was treated with 100 mg chlordiazepoxide. 5 days after administration of chlordiazepoxide, concentrations of chlordiazepoxide and its active metabolite demoxepam, were within therapeutic range, the patient was treated with flumazenil for 6 days. He died after palliative care.The great individual variation in the clinical effect of chlordiazepoxide depends on the activity of the CYP P450 system, especially CYP3A4/A5 and CYPS2C19, which can be impaired in cirrhotic and elderly patients.",

author = "Nanna Reiter and Andersen, {Charlotte U.} and Thomsen, {Karen L.} and Wamberg, {Christian A.} and Petersen, {Tonny S.} and Kim Dalhoff",

year = "2023",

month = jun,

day = "1",

doi = "10.1097/FAD.0000000000000068",

language = "English",

volume = "340",

pages = "1319--1322",

journal = "Adverse Drug Reaction Bulletin",

issn = "0044-6394",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

RIS

TY - JOUR

T1 - Risk of prolonged sedation with the use of chlordiazepoxide in alcohol withdrawal treatment

AU - Reiter, Nanna

AU - Andersen, Charlotte U.

AU - Thomsen, Karen L.

AU - Wamberg, Christian A.

AU - Petersen, Tonny S.

AU - Dalhoff, Kim

PY - 2023/6/1

Y1 - 2023/6/1

N2 - SummaryThe use of chlordiazepoxide in the treatment of alcohol withdrawal symptoms poses a risk of prolonged sedation with the need of weeks lasting antidote treatment, and extended hospitalization due to active metabolites with very long half-lives.We present four case stories to elucidate this issue. One patient received 800 mg chlordiazepoxide and was treated with flumazenil for 42 days. Another patient was treated with 100 mg chlordiazepoxide. 5 days after administration of chlordiazepoxide, concentrations of chlordiazepoxide and its active metabolite demoxepam, were within therapeutic range, the patient was treated with flumazenil for 6 days. He died after palliative care.The great individual variation in the clinical effect of chlordiazepoxide depends on the activity of the CYP P450 system, especially CYP3A4/A5 and CYPS2C19, which can be impaired in cirrhotic and elderly patients.

AB - SummaryThe use of chlordiazepoxide in the treatment of alcohol withdrawal symptoms poses a risk of prolonged sedation with the need of weeks lasting antidote treatment, and extended hospitalization due to active metabolites with very long half-lives.We present four case stories to elucidate this issue. One patient received 800 mg chlordiazepoxide and was treated with flumazenil for 42 days. Another patient was treated with 100 mg chlordiazepoxide. 5 days after administration of chlordiazepoxide, concentrations of chlordiazepoxide and its active metabolite demoxepam, were within therapeutic range, the patient was treated with flumazenil for 6 days. He died after palliative care.The great individual variation in the clinical effect of chlordiazepoxide depends on the activity of the CYP P450 system, especially CYP3A4/A5 and CYPS2C19, which can be impaired in cirrhotic and elderly patients.

U2 - 10.1097/FAD.0000000000000068

DO - 10.1097/FAD.0000000000000068

M3 - Review

AN - SCOPUS:85163026972

VL - 340

SP - 1319

EP - 1322

JO - Adverse Drug Reaction Bulletin

JF - Adverse Drug Reaction Bulletin

SN - 0044-6394

IS - 1

ER -

ID: 368254628

Institut for Klinisk Medicin